We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HAART Slows Brain Damage in AIDS Patients

By Biotechdaily staff writers
Posted on 23 Oct 2007
AIDS researchers have found that treatment with a combination of antiviral agents (HAART, or highly active antiretroviral treatment) reduces brain damage, which can be monitored by measuring the concentration of the light subunit of neurofilament protein in the cerebrospinal fluid (CSF). More...
The light subunit of neurofilament (NFL) protein is a sensitive indicator of central nervous system axonal injury.

Investigators at Goteborg University (Sweden) used an ELISA test to measure NFL protein concentrations in archived CSF samples taken from 53 AIDS patients before and after initiation of HAART. Elevated levels of NFL protein were found in the CSF of 21 patients before treatment. After three months of HAART the NFL protein level had dropped to normal values in ten of these patients. After a year of HAART only four of the patients retained high NFL protein levels.

Initially, 32 of the patients had normal NFL protein levels. Of these, only one experienced an increase to the pathological range over the course of the study.

Further results published in the October 9, 2007, issue of Neurology revealed that HAART seemed to halt the neurodegenerative processes caused by HIV-1, as shown by the significant decrease in CSF NFL protein after treatment initiation.

"This type of treatment appears to halt the neurodegenerative process caused by HIV,” said senior author Dr. Asa Mellgren, professor of infectious diseases at Goteborg University. "This study confirms that neurofilament light protein serves as a useful marker in monitoring brain injury in people with HIV and in evaluating the effectiveness of HAART.”


Related Links:
Goteborg University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.